The Prostate Cancer Center's laboratory research focuses on understanding the biology of prostate cancer to develop new drugs and treatments for prostate cancer. This research includes animal models of human prostate cancer in the laboratory and testing new drugs that will go into prostate cancer clinical trials, helping cancer patients as quickly as possible.
The Urologic-Oncology Research Program also focuses on basic science and translational research in prostate, kidney and bladder cancers.
Another focus of the Prostate Cancer Center research involves the use of gene chip analysis of prostate cancers. The development of the gene chip represents one of the most advanced developments in the area of biotechnology and is greatly enhancing prostate cancer research. This technology affords the ability to screen cell samples for gene expression (to determine which genes are turned "on" or "off") from among 95 percent of the expressed human genome in a relatively short period of time. By applying cancer cell samples to a gene chip, it becomes possible to screen a large number of relevant biochemical pathways for on and off switches. Use of this technology produces a massive acceleration of data acquisition, as thousands of genes may be screened in the timeframe of one experiment.
The Louis Warschaw Prostate Cancer Research Center's lab has been using gene chips to examine gene expression in human prostate samples from patients after prostatectomy, as well as in the xenograft models. In addition, the LWPCC lab is studying human prostate tumors in the laboratory and their response to standard and novel treatment regimens.
The Louis Warschaw Prostate Cancer Research Center has recently created the Clinical Outcomes Program to incorporate proteome and genome data together with machine learning algorithms to predict outcome of patients to therapeutic interpretation. This project includes a newly acquired fourier mass spectrometer and supercomputers.